Gilead Sciences and Eyetech Pharmaceuticals Announce Exclusive License of Potential New Therapy for Age-Related Macular Degeneration Eyetech Pharmaceuticals Signs Research Agreement With Massachusetts Eye and Ear Infirmary Eyetech Pharmaceuticals Raises $108.5 Million Through Private Equity Placement Dr. Anthony P. Adamis Joins Eyetech Pharmaceuticals to Lead Research Team Eyetech Completes Patient Enrollment For Two Pivotal Phase III Clinical Trials For Macular Degeneration - Early Completion of Patient Enrollment Triggers $54.2 Million in Funding Arda Ural Appointed Head of Marketing and Sales at Eyetech Pharmaceuticals Eyetech Pharmaceuticals Names Charles Williams as Senior Vice President, Manufacturing PFIZER, EYETECH PHARMACEUTICALS ENTER GLOBAL COLLABORATION FOR POTENTIAL TREATMENT FOR BLINDNESS EYETECH PHARMACEUTICALS TO PRESENT AT THE JP MORGAN 21ST ANNUAL HEALTHCARE CONFERENCE EYETECH PHARMACEUTICALS ENTERS DEAL FOR XALATAN, WORLD’S TOP-SELLING OPHTHALMIC MEDICATION Eyetech Pharmaceuticals Appoints General Counsel, Expands Commercial Team